Bristol-Myers Posts Q1 Beat Despite Growth Headwinds
Seeking AlphaApr 25 07:56 ET
Express News | 2Seventy Bio Inc: Abecma (Idecabtagene Vicleucel, or Ide-Cel) Generated Approximately $52 Mln in U.S. Revenue During Q1 of 2024
ReutersApr 25 07:08 ET
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-related caution for medications—for all chimeric antige
BenzingaApr 19 09:28 ET
FDA Requires Labeling Changes to CAR-T Cell Therapies to Reflect Cancer Risk
Seeking AlphaApr 19 06:13 ET
Express News | 2Seventy Bio Said Co, Bristol Myers Squibb Announced That FDA Approved Use Of Suspension Lentiviral Vector For Manufacturing Of Abecma
Moomoo 24/7Apr 9 07:06 ET
2seventy Bio Is Maintained at Buy by Citigroup
2seventy Bio Is Maintained at Buy by Citigroup
Dow JonesApr 8 18:23 ET
Express News | Citigroup Maintains Buy on 2seventy Bio, Raises Price Target to $12
Moomoo 24/7Apr 8 18:12 ET
2seventy Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/08/2024 118.18% Citigroup $9 → $12 Maintains Buy 03/18/2024 -9.09% Wedbush → $5 Reiterates Neutral → Ne
BenzingaApr 8 18:11 ET
Positive Outlook for 2seventy Bio's ABECMA: Buy Rating Affirmed Amidst Expansion and Competitive Dynamics
TipRanksApr 8 07:25 ET
Buy Rating and High Risk for 2seventy Bio: FDA Approval and Market Expansion Fuel Optimistic Outlook
TipRanksApr 7 15:05 ET
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
Friday, the FDA approved Bristol-Myers Squibb Company (NYSE:BMY) and 2seventy Bio Inc's (NASDAQ:TSVT) Abecma (idecabtagene vicleucel; ide-cel) for adult patients with relapsed or refractory multiple
BenzingaApr 5 13:37 ET
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication
Bristol-Myers Squibb (BMY) and 2seventy bio (TSVT) said Friday that the US Food and Drug Administration has approved the expansion of the indication of the companies' myeloma treatment Abecma. The app
MT NewswiresApr 5 10:20 ET
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma
By Colin Kellaher Bristol Myers Squibb and 2seventy bio have won U.S. Food and Drug Administration approval for the earlier use of their Abecma gene therapy in the treatment course for people with th
WSJApr 5 09:17 ET
Express News | At An Estimated Median Duration Of Follow-Up Of 15.9 Months At The Primary PFS Analysis, Abecma More Than Tripled The Primary Endpoint Of PFS Compared With Standard Regimens
Moomoo 24/7Apr 5 09:09 ET
MGNX, SBNY and SLP Are Among After Hour Movers
Seeking AlphaApr 3 17:24 ET
2seventy Bio Finalizes Asset Sale and Executive Transition
TipRanksApr 1 08:02 ET
2seventy Bio: Will No Exclusively Focused on Development and Commercialization of Abecma >TSVT
2seventy Bio: Will No Exclusively Focused on Development and Commercialization of Abecma >TSVT
Dow JonesApr 1 07:31 ET
2seventy Bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
2seventy Bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
Dow JonesApr 1 07:30 ET
2seventy Bio(TSVT.US) Director Buys US$203.99K in Common Stock
$2seventy bio(TSVT.US)$ Director Casdin Capital, LLC purchased 40,000 shares of Common Stock on Mar 26, 2024 at an average price of $5.0998 for a total value of $203.99K. This transaction involves oth
moomoo NewsMar 28 21:09 ET
2seventy Bio(TSVT.US) Director Buys US$3.9 Million in Common Stocks
$2seventy bio(TSVT.US)$ Director Casdin Capital, LLC purchased 777.38K shares of Common Stocks on Mar 21, 22, 25, 2024 at an average price of $5.0156 for a total value of $3.9 million. This transactio
moomoo NewsMar 25 22:28 ET
No Data
No Data